Liu, Chang
Somasundaram, Ashwin
Manne, Sasikanth
Gocher, Angela M.
Szymczak-Workman, Andrea L.
Vignali, Kate M.
Scott, Ellen N.
Normolle, Daniel P.
John Wherry, E. http://orcid.org/0000-0003-0477-1956
Lipson, Evan J. http://orcid.org/0000-0003-2976-0911
Ferris, Robert L.
Bruno, Tullia C.
Workman, Creg J.
Vignali, Dario A. A. http://orcid.org/0000-0002-2771-5992
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA203689, AI108545, CA082084, CA247004-01, AI117950, AI082630, AI112521, AI115712, AI108545, CA210944)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA047904, CA006973, CA047904, CA097190)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 12 May 2019
Accepted: 9 June 2020
First Online: 13 July 2020
Competing interests
: D.A.A.V. declares competing financial interests and has submitted patents covering Nrp1 that are licensed or pending and is entitled to a share in net income generated from licensing of these patent rights for commercial development. D.A.A.V. consults for and/or is on the scientific advisory board of Tizona, Werewolf, F-Star, Astellas/Potenza, BMS, Oncorus, Innovent Bio, Kronos Bio and G1 Therapeutics; has grants from BMS, Astellas/Potenza, Tizona and TTMS; patents licensed and royalties from Astellas/Potenza, Tizona and BMS; and stock from TTMS, Tizona, Potenza, Oncorus and Werewolf. R.L.F. consults for and/or is on the scientific advisory board for Aduro Biotech, Inc., Astra-Zeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, GlaxoSmithKline, Iovance Biotherapeutics, Inc., MacroGenics, Inc., Merck, Nanobiotix, Numab Therapeutics AG, Oncorus, Inc., Ono Pharmaceutical Co. Ltd, PPD (Benitec, Immunicum), Regeneron Pharmaceuticals, Inc., TTMS and Torque Therapeutics Inc. R.L.F. receives research funding from Astra-Zeneca/MedImmune, Bristol-Myers Squibb, Tesaro and TTMS and has stock from TTMS. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. has a patent licensing agreement on the PD1 pathway with Roche/Genentech. E.J.L. consults for Array BioPharma, Bristol-Myers Squibb, EMD Serono, MacroGenics, Novartis, Merck, Regeneron and Sanofi Genzyme. E.J.L. receives research funding from Bristol-Myers Squibb, Merck and Regeneron.